Erythromycin (gluceptate)
Erythromycin gluceptate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin gluceptate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin gluceptate also exhibits antitumor and neuroprotective effect in different fields of research[3][4].
For research use only. We do not sell to patients.
- CAS No.: 23067-13-2
- Formula: C44H81NO21
- Molecular Weight:960.11
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
|
Macrolide |
Erythromycin gluceptate inhibits growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[1].
Erythromycin gluceptate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat)
-
Concentration:10, 100 μM
-
Incubation Time:24, 72 hours
-
Result:Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD).
Erythromycin gluceptate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg[3].
Erythromycin gluceptate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female ddY mice (6-week-old) with EAC cells or CDF mice (6-week-old) with P388 cells[3]
-
Dosage:0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
-
Administration:Gastric intubation; 30-120 days
-
Result:Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.
-
Animal Model:Male Sprague-Dawley rats (8-week-old, 250-300 g)[4]
-
Dosage:50 mg/kg
-
Administration:Subcutaneous single injection
-
Result:Reduced infarct volume and edema volume, improved neurological deficit.
Chemical Information
-
CAS No. 23067-13-2
-
Molecular Weight 960.11
-
Formula C44H81NO21
-
SMILES
O[C@H]([C@@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)C(O)=O.O[C@H]([C@H](C[C@@H](C)O1)N(C)C)[C@]1([H])O[C@@H]2[C@H]([C@@H]([C@H](C(O[C@@H]([C@@](C)(O)[C@H](O)[C@@H](C)C([C@H](C)C[C@]2(O)C)=O)CC)=O)C)O[C@@]3([H])C[C@](C)([C@@H](O)[C@H](C)O3)OC)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. [Content Brief]
[2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec. 100(3):185-91. [Content Brief]
[3]. K Hamada, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69. [Content Brief]
[4]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz